Blood

Vol. 146, Issue Supplement 1 Issue Supplement 1 2025
8248
Articles

Articles in this Issue

Phase I/Ⅱ study evaluating the safety and preliminary efficacy of amulirafusp alfa (IMM0306) in combination with lenalidomide in patients with relapsed/refractory CD20-positive follicular lymphoma

Yan Huang, Yanyan Liu, Hongming He et al. Nov 03, 2025 pp. 5358-5358 10.1182/blood-2025-5358

Abstract Background: Follicular lymphoma (FL) is characterized by a relapsing and incurable course, wherein patients require multiple lines...

Hetrombopag for the treatment of chemotherapy-induced thrombocytopenia in advanced solid tumors: A multicenter, randomized, double-blind, placebo-controlled phase III trial

ShuKui Qin, Yanqiao Zhang, Hongli Li et al. Nov 03, 2025 pp. 1256-1256 10.1182/blood-2025-1256

Abstract Introduction: Chemotherapy-induced thrombocytopenia (CIT) is a common complication resulting from the myelosuppressive effects of c...

Inhibition of the aryl hydrocarbon receptor eliminates leukemia stem cells in murine models of Acute Myeloid Leukemia

Alyona Oryshchuk, Rhea Desai, Hui Mei Lee et al. Nov 03, 2025 pp. 6101-6101 10.1182/blood-2025-6101

Abstract Leukaemia stem cells (LSCs) not only drive and sustain acute myeloid leukemia (AML), but also frequently survive chemotherapy and c...

Donor age matters: Selecting 10/10 muds under 35 enhances survival after ptcy allo-HCT

Daniel Munárriz Lorca, Estefanía Pérez López, Carlos Martín-Rodriguez et al. Nov 03, 2025 pp. 7825-7825 10.1182/blood-2025-7825

Abstract INTRODUCTION Allogeneic hematopoietic cell transplantation (allo-HCT) from a 10/10 HLA-matched unrelated donor...

Comparison of haploidentical donors for pediatric patients undergoing hematopoietic stem cell transplantation: 10-year outcomes from a single-center experience

Paulina Garcia Maldonado, Ginna Romero, Julia Esther Colunga-Pedraza et al. Nov 03, 2025 pp. 7769-7769 10.1182/blood-2025-7769

Abstract Introduction: Donor age is one of the main prognostic factors in haploidentical transplantation, particularly in relation to the in...

Balancing the treatment outcomes: Survival and quality of life among older adults with AML

Sara Tinsley-Vance, Cecile Lengacher, David Sallman et al. Nov 03, 2025 pp. 6405-6405 10.1182/blood-2025-6405

Abstract Background: The treatment of older adults with acute myeloid leukemia( AML) is rapidly changing. Survival in this population has hi...

Long-term follow-up of a prospective phase 2 Study of daratumumab plus bortezomib and dexamethasone in newly diagnosed mayo 2004 stage IIIA and IIIb light-chain amyloidosis

Xuemin Gao, Kaini Shen, Yajuan Gao et al. Nov 03, 2025 pp. 3965-3965 10.1182/blood-2025-3965

Abstract Introduction Mayo 2004 stage IIIB primary light chain amyloidosis (AL) patients exhibit poor outcomes and were excluded from most cl...

Longitudinal analysis of T-cell phenotype and function during bispecific antibody therapy

Akiva Diamond, Sandy Reid, Cliona Rooney Nov 03, 2025 pp. 5346-5346 10.1182/blood-2025-5346

Abstract Introduction Bispecific antibodies (BsAbs) linking CD3 on T cells to CD20 on lymphoma cells (CD3xCD20) or to BC...

Distinct patterns of mutant ASXL1 over time and their implications for treatment failure (TF) and BCR::ABL1 mutation development in newly diagnosed patients with chronic myeloid leukemia in chronic phase (CML-CP) treated with asciminib (ASC) vs investigator-selected tyrosine kinase inhibitors (IS-TKI) in the ASC4FIRST study

Susan Branford, Jorge Cortés, Naoto Takahashi et al. Nov 03, 2025 pp. 73-73 10.1182/blood-2025-73

Abstract Introduction: ASC, an allosteric BCR::ABL1 inhibitor, was recently approved in several countries for use in newly diagnosed patient...

Mis-splicing of Mdm4 activates TRP53 and impairs HSPC growth in a mouse model of myelodysplastic syndromes

Stefan Tarnawsky, Alondra Colón Vega, Sridhar Srivatsan et al. Nov 03, 2025 pp. 230-230 10.1182/blood-2025-230

Abstract Mutations in splicing factor genes (e.g. human U2AF1, SRSF2, SF3B1 and mouse U2af1, Srsf2, Sf3b1) occur in up to 50% of patients wi...

Transcriptional stratification reveals distinct molecular subtypes with treatment-specific outcomes in multiple myeloma patients from the GEM2017FIT trial

Antonio Porlan, Beñat Ariceta, Paula Aguirre-Ruiz et al. Nov 03, 2025 pp. 496-496 10.1182/blood-2025-496

Abstract INTRODUCTION Multiple myeloma (MM) is a genetically and clinically heterogeneous plasma cell malignancy that remains incurable desp...

A partial neutralizing antibody to Protein C: Hemophilic bleeding preventive effects and thrombotic risks in nonhuman primates

Takehisa Kitazawa, Atsushi Muto, Tetsuhiro Soeda et al. Nov 03, 2025 pp. 1276-1276 10.1182/blood-2025-1276

Abstract The Protein C (PC) system maintains proper control of fibrin formation in hemostasis by downregulating the coagulation propagation...

Inhibition of DRP1–FIS1–Mediated mitochondrial fission as a novel strategy to prevent gvhd

Hao Yan, Vijith Vijayan, Chun-Hsien Chiang et al. Nov 03, 2025 pp. 2310-2310 10.1182/blood-2025-2310

Abstract Graft-versus-host disease (GVHD) remains a leading cause of non-relapse mortality following hematopoietic stem cell transplantation...

Evaluating patient preferences for chronic lymphocytic leukemia (CLL) in Korea: A discrete choice experiment

Byung Woo Yoon, Suhyeon Lee, Mei Xue et al. Nov 03, 2025 pp. 7923-7923 10.1182/blood-2025-7923

Abstract Introduction: CLL disease control and survival outcomes have improved since the introduction of Bruton tyrosine kinase inhibitors (...

Which molecular patterns of high-risk myeloid malignancies are concordantly identified using two machine learning algorithms?

Tariq Kewan, Arda Durmaz, Waled Bahaj et al. Nov 03, 2025 pp. 3485-3485 10.1182/blood-2025-3485

Abstract Background: Higher-risk myelodysplastic syndromes/neoplasms (HR-MDS) and secondary acute myeloid leukemia (sAML) share overlapping m...

Risk of relapse and mortality after non-myeloablative allogeneic stem cell transplant for Acute Myeloid Leukemia and myelodysplastic syndrome after fludarabine, cyclophosphamide, and 200 centigray total body irradiation  with gvhd prophylaxis using post-transplant cyclophosphamide, sirolimus, and mycophenolate mofetil: Impact of maintenance chemotherapy

Christopher Graham, Roy Kao, Qing Cao et al. Nov 03, 2025 pp. 7781-7781 10.1182/blood-2025-7781

Abstract Introduction: Allogeneic hematopoietic stem cell transplantation (allo-HSCT) can be curative for patients with high-risk myeloid ma...

Epigenetic targeting of SETD8 in multiple myeloma

Rudra Prasad Dutta, He Chen, Yue Zhong et al. Nov 03, 2025 pp. 3310-3310 10.1182/blood-2025-3310

Abstract Background: Multiple myeloma (MM) is a plasma cell malignancy and the second most common hematologic cancer. Despite effective front...

Post partum haemorrhage (PPH): Differences in coagulation patterns between vaginal deliveries and c-section - and why prophylactic txa is unlikely to be of advantage

Wolfgang Korte, Christian Haslinger, Justus Bürgi Nov 03, 2025 pp. 3085-3085 10.1182/blood-2025-3085

Abstract Introduction: We earlier showed prepartum F XIII to be the main coagulation component to influence postpartum blood loss (PPBL) ove...

Real-world effectiveness and safety of belumosudil in pediatric chronic graft-versus-host disease: A retrospective cohort study

Min Zhou, Jun Lu, Peifang Xiao et al. Nov 03, 2025 pp. 6026-6026 10.1182/blood-2025-6026

Abstract Background: Chronic graft-versus-host disease (cGVHD) remains a leading cause of non-relapse mortality and morbidity in pediatric p...

Refined genetic risk model with complex karyotype predicts outcomes of newly diagnosed acute myeloid leukemia treated with decitabine plus venetoclax

Razan Mohty, Kendall Diebold, Todd Mudd et al. Nov 03, 2025 pp. 5272-5272 10.1182/blood-2025-5272

Abstract Introduction: The European LeukemiaNet (ELN) developed a new genetic risk score (ELN2024) for patients (pts) with newly diagnosed (...

Dynamic changes in the bone marrow niche following CD19-targeted CAR-T cell infusion in diffuse large B cell lymphoma (DLBCL).

Timothy Shaw, Melanie Mediavilla Varela, Alyssa Obermayer et al. Nov 03, 2025 pp. 5881-5881 10.1182/blood-2025-5881

Abstract Introduction CAR T cells have changed the treatment landscape of relapse/refractory (RR) DLBCL, offering a curative option. About h...

Mid-treatment CSF ctdna and MYD88 clearance outperform PET-CT in predicting response and survival to orelabrutinib-based induction in newly diagnosed PCNSL: A prospective biomarker study

Lixia Sheng, Yanli Lai, Sheng Nie et al. Nov 03, 2025 pp. 59-59 10.1182/blood-2025-59

Abstract Background Primary central nervous system lymphoma (PCNSL) is an aggressive extranodal non-Hodgkin lymphoma with limited tools for...

Incidence of asymptomatic deep vein thrombosis in patients with tunneled dialysis catheters undergoing routine venous mapping.

Bibi Maryam, Adolfo Diaz Barba, Yusra Nasir et al. Nov 03, 2025 pp. 4917-4917 10.1182/blood-2025-4917

Abstract Background: Tunneled dialysis catheters (TDCs) are widely used for hemodialysis access but are associated with...

Plasma protein biomarkers associated with venous thromboembolism (VTE) and mortality in patients with cancer: A substudy of the avert trial

Mehrie Patel, John Barnard, Marc Carrier et al. Nov 03, 2025 pp. 3127-3127 10.1182/blood-2025-3127

Abstract Background: Cancer is associated with a substantially elevated risk of venous thromboembolism (VTE), but this risk varies considerab...

Outcomes of inpatient and outpatient chimeric antigen receptor T-cell therapy (CAR T) in newly authorized treatment centers (ATCs) in the United States (US)

Olalekan Oluwole, Hil Hsu, Samuel Hong et al. Nov 03, 2025 pp. 6284-6284 10.1182/blood-2025-6284

Abstract Introduction: CAR T has transformed the treatment landscape for hematologic malignancies. Despite its clinical success, access to C...

All Issues

Journal Info

Publisher Elsevier BV
ISSN 0006-4971
E-ISSN 1528-0020
Subject Health Sciences
Language English
View Full Journal Page